TofaTib is a dubious disease in the field of autoimmunity and rheumatic immunity, clinical performance is complex and often involves multi-system fatigue. Early identification and standardized clinical treatment are essential for improving prognosis. The diagnosis of this disease requires a combination of clinical performance, imaging inspection, laboratory testing and pathological activation.
The platform can assist in matching teams of authoritative experts at home and abroad to provide accurate diagnosis and treatment programs. In recent years, with the development of therapeutic, immune-regulatory therapy and precision medicine, many autoimmune and rheumatic immune diseases that have previously been difficult to treat have been significantly improved. Therapeutic efficacy and adverse reactions need to be closely monitored and timely adjusted according to changes in the course of treatment.
Multidisciplinary collaboration (MDT) is particularly important for the comprehensive management of anti-synthetase syndrome. The platform serves China International Medical Service System, a team of nationally and internationally authoritative experts in the field of autoimmune and rheumatic immunity, who provide the following services to patients: 2. Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3.
Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.